Publications by authors named "Nobuo Funao"

Claim this Profile
V
Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.
Yinglian Xiao, Jiaming Qian, Shutian Zhang, Ning Dai, Hoon Jai Chun, Nobuo Funao

Chin Med J (Engl)· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Yinglian Xiao, Shutian Zhang, Ning Dai, Guijun Fei, Khean-Lee Goh, Nobuo Funao

Gut· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Yuji Mizokami, Kazunori Oda, Nobuo Funao, Akira Nishimura, Satoshi Soen

Gut· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Takashi Kawai, Kazunori Oda, Nobuo Funao, Akira Nishimura, Yasushi Matsumoto

Gut· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to the letter by Dr Graham concerning ethical and interpretation issues with vonoprazan-containing H. pylori eradication therapy.
Kazunari Murakami, Yuuichi Sakurai, Madoka Shiino, Nobuo Funao, Akira Nishimura

Gut· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Kazunari Murakami, Yuuichi Sakurai, Madoka Shiino, Nobuo Funao, Akira Nishimura

Gut· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
Nobuya Inagaki, Hitoshi Onouchi, Hiroki Sano, Nobuo Funao, Shingo Kuroda

Lancet Diabetes Endocrinol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis